MGI Empowers European Genomics with the Launch of MGISP-Smart 8 and Empowerment Program at MEDICA

8 мар. 2023 г.

News

Düsseldorf, Germany

MGI Empowers European Genomics with the Launch of MGISP-Smart 8 and Empowerment Program at MEDICA
MGI Empowers European Genomics with the Launch of MGISP-Smart 8 and Empowerment Program at MEDICA
MGI Empowers European Genomics with the Launch of MGISP-Smart 8 and Empowerment Program at MEDICA
MGI Empowers European Genomics with the Launch of MGISP-Smart 8 and Empowerment Program at MEDICA

MGISP-Smart 8 A New Era in Lab Automation

The MGISP-Smart 8, a groundbreaking lab automation platform, was unveiled to great acclaim at MEDICA. This dynamic system, equipped with an 8-channel independent pipetting robot, delivers exceptional lab automation versatility. Whether for sequencing library preparation, nucleic acid detection, or sample preparation, MGISP-Smart 8 is an optimal choice for a wide array of applications.

Bearing a suite of advanced technologies like the intelligent integrated gripper and triple slide track design, the MGISP-Smart 8 enables efficient and precise operations. It stands out with its independent multi-channel dynamic positioning and dual-level liquid detection, enhancing the reliability and accuracy of sample handling. This system empowers genomics researchers and clinicians to achieve remarkable results and progress in their work.

MGISP-Smart 8 A New Era in Lab Automation

The MGISP-Smart 8, a ground breaking lab automation platform, was unveiled to great acclaim at MEDICA. This dynamic system, equipped with an 8-channel independent pipetting robot, delivers exceptional lab automation versatility. Whether for sequencing library preparation, nucleic acid detection, or sample preparation, MGISP-Smart 8 is an optimal choice for a wide array of applications.

Bearing a suite of advanced technologies like the intelligent integrated gripper and triple slide track design, the MGISP-Smart 8 enables efficient and precise operations. It stands out with its independent multi-channel dynamic positioning and dual-level liquid detection, enhancing the reliability and accuracy of sample handling. This system empowers genomics researchers and clinicians to achieve remarkable results and progress in their work.

Empowering Genomics through Collaboration

The launch of our Empowerment Program coincided with this year's MEDICA event. This program is a testament to our commitment to fostering collaboration with diagnostic companies and public institutions. The aim is to develop library preparation kits that are fully compatible with MGI sequencing platforms, thereby accelerating the IVDR certification process and providing more choices in the sequencing field.

The Empowerment Program grants participating companies access to our proprietary DNBSEQ™ technology, featuring MGI's HotMPS chemistry. This technology has catalyzed breakthroughs in areas such as oncology and reproductive health. By extending this opportunity to our partners, we strive to make a significant collective impact on patient care and health outcomes.

Building Strong Collaborations for Future Healthcare

At MGI, we champion the potential of genomics. By sharing our expertise and technical resources, we enable more companies and institutions to seamlessly leverage our DNBSEQ™ platforms. Through collaboration, we aim to empower researchers and clinicians in their pursuit of advancing health and well-being for all.

We have fostered successful collaborations with notable technology platforms, such as VarSome in Switzerland and ALACRiS Theranostics in Germany. These partnerships have enabled us to offer expert solutions for high-throughput sequencing users and comprehensive end-to-end solutions for cancer diagnostics. Through the Empowerment Program, we aim to extend our support to more organizations across Europe.

A Successful Showcase at MEDICA

MEDICA was a wonderful opportunity for our valued customers, distributors, and partners to explore our high-quality sequomics. We thank everyone who joined us in this pivotal event and look forward to future opportunities to showcase our commitment to advancing genomics and providing innovative solutions to pressing health challenges. Our presence at MEDICA allowed us to build strong relationships, gain valuable feedback, and learn more about the needs of the healthcare community. We are excited about the potential these connections hold for the future of genomics and the meaningful impact our technologies can have on patient care. We are grateful to MEDICA for the platform and to all attendees for the engaging discussions.

 

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

MGISP-Smart 8

Automation

Düsseldorf

Germany

Share this article :

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer
Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

4 мар. 2024 г.

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe.

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

10 нояб. 2023 г.

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Latvia MGI Tech SIA advances DNA methylation research with significant European funding, achieving groundbreaking progress in biotechnology and innovation.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment
MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

10 июл. 2023 г.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Explore MGI's latest achievement as its DNBSEQ-T20×2 gene sequencing platform wins the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This post highlights MGI's commitment to innovation in the life science industry, their groundbreaking T20 gene sequencer, and how their technology is reshaping healthcare outcomes and the genetic industry.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.